Deck 5 - GU Flashcards
Q. Name a primary, secondary and tertiary technique for the prevention of HIV transmission
A. Primary prevention: reducing risk of acquiring STI (condoms, STI awareness campaigns, one-one risk discussion, vaccination, pre/post exposure prophylaxis)
B. Secondary prevention: aims to find and treat undetected cases of infection, thereby removing from community pool (increasing access to STI/HIV tests and treatment (confidential, self-referral, drop in, short waiting lists), targeted screening, partner notification
C. Tertiary prevention: treatment - reducing morbidity / mortality (anti-retrovirals for HIV, prophylactic antibiotics for PCP, acyclovir for suppression of genital herpes)
Q. Describe three differences between chlamydia and gonorrhoea
A. Chlamydia: most common, asymptomatic carriage more common
B. Gonorrhoea: less common, clinical manifestations more florid, diagnosis
associated with recent partner change, more prone to Abx resistance
Q. Describe the symptoms of chlamydia and gonorrhoea, what complications mayoccur?
A. Male: dysuria and urethral discharge, asymptomatic
a. Complications: epididymo-orchitis, reactive arthritis
B. Female: non-specific discharge, menstrual irregularity, dysuria, asymptomatic
a. Complications: pelvic inflammatory disease, tubal factor infertility, sctopic pregnancy, chronic pelvic pain, neonatal transmission (ophthalmic neonatorum, atypical pneumonia with CT), Fitz Hugh Curtis syndrome
(peri-hepatitis)
Q. How is chlamydia diagnosed?
A. Nucleic Acid Amplification Tests (NAAT)
B. High specificity and sensitivity
C. Female
– Self collected vaginal swab
– Endocervical swab
– First void urine – lower sensitivity. Sometimes used in community based
asymptomatic screening
D. Male – First void urine
Q. Describe chlamydia treatment
A. Azithromycin 1gram stat or doxycycline 100mg bd for 7 days – low resistance risk
B. Erythromycin 500mg bd for 14 days for azithromycin 1 gram stat in pregnancy
C. Also: test for other STIs, partner management
Q. How is gonorrhoea diagnosed?
Near patient testing: swabs of genital secretions from: male – urethra, female –
endocervix, rectum
B. Microscopy looking for gram –ve diplococci within cytoplasm of polymorphs
C. Culture on selective medium to confirm diagnosis, sensitivity testing
D. Nucleic acid amplification test
Q. How should gonorrhoea be treated?
A. Ceftriaxone 500mg IMI with Azithromycin 1 gram orally stat
B. Others: test for other STIs, partner notification, single dose Tx preferred,
continuous surveillance of Abx resistance
Q. Who is at a higher risk of contracting syphilis?
A. Men who have sex with men – unprotected anal intercourse
B. Also highly transmissible through oral sex
Q. Describe the stages/phases associated with syphilis
A. Primary: incubation 9-90, usually 21-25 days – 95% genital skin, nipples, mouth
a. Dusky macule, regional nodes, untreated heals without scaring
B. Secondary: onset 6-8/52 after infection
a. 70% present with skin rash, others: mucous membrane lesions,
generalised lymphadenopathy, alopecia (moth-eaten), hoarseness, bone
pain, hepatitis, nephrotic syndrome, deafness, iritis, meningitis, cranial
nerve palsies, constitutional
C. Late syphilis: (if untreated) – late benign gummatous (2-40yrs), neurosyphilis, (2-
40yrs), General paresis (cerebral atrophy, 10-15yrs), tabes dorsalis (slow
degeneration of neural tracts in dorsal columns – gait, lightening pains and
urinary incontinence) 15-35yrs, cardio (20-30yrs)
Q. How is syphilis diagnosed?
A. Serology: usually +ve if ulcer present for 2+ weeks, if serology –ve repeat at 6 and
12 weeks to exclude diagnosis
B. Genital ulcer – primary, rash – secondary syphilis
C. Confirmatory test for screening +ve tests, TPPA – Treponema pallidum particle
agglutination test, (also VDRL or RPR)
Q. What occurs in AD Tubulointerstitial kidney disease?
A. Renal cysts and diabetes syndrome (50% lifetime risk)
B. Associated with: gout, hypomagnesaemia, deranged LFTs, abnormal genital tract
C. Abnormal renal development (not necessarily cysts: single/horseshoe kidney,
abnormal renal pelvis)
D. AD – mutation in HNF1 beta – ch17q12
Q. What occurs in renal cystic disease?
A. Autosomal recessive: rare (1/20000), mutation in PKHD1, diagnosed antenatal or neonatal
B. Enlarged poly cystic kidneys
C. Associated with: hepatobiliary problems – Cong. Hepatic fibrosis, cholangitis, portal HTN, Pulmonary hypoplasia – leads to mortality (30%)
D. 30% develop kidney failure – dialysis/combined liver-kidney transplantation
Q. What is medullary sponge kidney?
A. Cystic dilation of collecting tubule, mostly sporadic, usually diagnosed
incidentally in adult hood
B. May be uni/bilateral
C. Benign* but associated with other complications: UTI, renal stones, renal tubular
acidosis, rarely - CKD
Q. What occurs in nephronophthisis?
A. Disappearance of nephrons
B. Kidneys tend to be smaller, very rare condition, causes kidney failure in 7% of children (UK), >20 casual genes
C. Associated problems (10-15% of cases): retinal problems – rentinitis pigmentosa (early cause of blindness), Neurodevelopmental delay, Hepatic fibrosis (10-15%)
Q. What is the most common inherited kidney disease? What occurs?
A. AD polycystic kidney disease (ADPKD)
B. Gradual, progressive cysts development and growth, Wide variability in
progression, onset 56-80yrs dependent on genetic mutation
C. Causal genes: PKD1 (85%) and PKD2 (15%)